

1 **Regulation of Inducible Nitric Oxide Synthase by Arabinoxylans with Molecular**
2 **Characterization from Wheat Flour in Cultured Human Monocytes**

3 Zhengxiao Zhang,¹ Christopher Smith,² Jason Ashworth,³ and Weili Li ^{2*}

4 ¹ Department of Medical Microbiology and Department of Animal Science, University of
5 Manitoba, Winnipeg, MB, Canada, R3T 2N2

6 ² Institute of Food Science and Innovation, University of Chester, Chester, CH1 4BJ, UK.

7 ³ School of Healthcare Science, Manchester Metropolitan University, Manchester, M1 5GD, UK

8 * *Corresponding author at: Institute of Food Science and Innovation, University of Chester, Chester,*
9 *CH1 4BJ, UK*

10 *Tel: +44 1244511397; E-mail: w.li@chester.ac.uk*

11

12

13 **Abstract**

14 The immunomodulatory activity of the arabinoxylans (AXs) extracts from cereal sources
15 have been reported to impart health benefits in terms of immune enhancement. This
16 study investigated the effect of enzymatic extraction on extraction yield and structure of
17 AXs from wheat flour pentosan fraction. Under the optimised conditions, the extraction
18 yield of AXs reached up to 81.25%. Furthermore, the study determined whether water-
19 extracted AXs (WEAXs) and enzyme-extracted AXs (E-WEAXs) from wheat flour were
20 able to differentially stimulate nitric oxide (NO) secretion through increased levels of
21 inducible nitric oxide synthase (iNOS) in human U937 monocytes. The results indicated
22 that AXs concomitantly induced ($P < 0.05$) both NO and iNOS productions in U937
23 monocytes compared to untreated cells. Compared with WEAXs, E-WEAXs resulted in a
24 higher proportion of low Mw (1-10 KDa) AXs (49.51% versus 19.11% in WEAXs), a
25 higher A/X ratio (0.83 versus 0.48 in WEAXs) and a higher yield ($12.83 \pm 0.35\%$ versus
26 $7.54 \pm 0.47\%$ in WEAXs). Moreover, E-WEAXs induced significantly ($P < 0.05$) greater NO
27 and iNOS production per million viable cells ($61.8 \pm 2.7 \mu\text{M}$ and $42.41 \pm 3.83 \text{ ng}$
28 respectively) than WEAXs ($51.6 \pm 2.6 \mu\text{M}$ and $33.46 \pm 1.48 \text{ ng}$ respectively). The findings
29 suggest AXs may heighten innate immune activity in the absence of infection or disease

30 through an iNOS-mediated stimulation of NO production. The immunomodulatory
31 activity of the wheat-derived AXs was enhanced by enzyme treatment, with low Mw and
32 high A/X ratio associated with elevated NO/iNOS levels in human monocytes compared
33 to water-extraction.

34 **Keywords:** *arabinoxylans; wheat flour; extraction; molecular structures; immunomodulatory*
35 *activity; nitric oxide; inducible nitric oxide synthase*

36

37 **Introduction**

38 Arabinoxylans (AXs) are hemicelluloses found in the outer-layer and endosperm cell
39 walls of cereal grains, such wheat and corn (Izydorczyk and Biliaderis 2007, Fan *et al.*
40 2016, Li *et al.* 2016). It has been reported that oral administrated dietary fibre including
41 β -glucans and AXs is able come into contact with the mucosal immune system (Mendis *et*
42 *al.* 2016), in which intestinal epithelial cells together with the immune cells of the
43 Peyer's patches play an important role in regulating immune responses (Smith *et al.*
44 2011). Previous animal study also showed oral administration of AXs (1.6 – 3.2 mg/day)
45 significantly induced intestinal macrophage phagocytosis, delayed the hypersensitivity
46 reaction and increased spleen lymphocyte proliferation (Zhou *et al.* 2010). Moreover, a
47 human study involving 80 participants showed that consumption of rice-derived AXs as
48 a dietary supplement (3 g/day for 8 weeks) significantly increased interferon gamma
49 (IFN- γ) production in circulating leukocytes of healthy adults (Choi *et al.* 2014),
50 confirming immunomodulatory effects of AXs on human peripheral blood mononuclear
51 cells. Thus, AXs may be considered a bioactive food supplement with immunity
52 improvement properties (Zhang *et al.* 2015). However, the role of AXs in certain specific

53 immune responses, including the expression of nitric oxide (NO) synthases and
54 downstream NO secretion, remains largely undetermined. The immune functions of NO
55 have been found to involve antimicrobial and anti-tumour activities *in vitro* and *in vivo*
56 (Lechner *et al.* 2005, Bogdan 2000). Inducible NO synthase (iNOS) is one isoform in a
57 family of NOS enzymes involved in the generation of NO from L-arginine. Expression of
58 iNOS in immune cells is induced during an immune response following stimulation by
59 microbial polysaccharides such as lipopolysaccharides (LPS) and immune cytokines
60 (Bogdan 2000). Recent studies have shown that AXs enhance NO secretion in both
61 murine and human monocyte/macrophage cell lines (Nagata *et al.* 2001, Ghoneum and
62 Matsuura 2004). However, the precise mechanism through which NO secretion is
63 stimulated by AXs has not been elucidated to date.

64 In addition, the molecular characteristics, such as the molecular weight (Mw) and
65 substitution degree (A/X) of cereal AXs, appear to affect their NO-inducing activities
66 (Zhou *et al.* 2010, Zhang *et al.* 2016). The endo- β -(1,4)-xylanases (EC 3.2.1.8) are
67 commonly involved in cereal AXs isolation and structural modification (Zhang *et al.* 2014).
68 The yields of AX extracts using enzymatic treatment showed generally low. Van Craeyveld

69 *et al.* (2010) extracted 32-55% of the wheat bran AX using 3 different endoxylanase
70 treatments, and Escarnot *et al.* (2012) tested various xylanases on the AXs extraction yield
71 of spelt bran and hull and the highest extraction recovery was 68.8% of the total AX of raw
72 materials. The pentosan fraction of wheat flour is a by-product of wheat starch processing,
73 and it has been found to be an AX-enriched source that usually consists of about 12%
74 original AXs content (Li *et al.* 2013). However, the effects of extraction and modification
75 conditions using enzymatic treatment on the yield and molecular structures of AXs from
76 the pentosan of wheat flour have been limited reports. Thus, for the first time, this study
77 investigated whether the iNOS isoform of the NOS enzymes mediates NO production in
78 U937 human monocytes following treatment with AXs from wheat flour. Moreover, the
79 differential influence of the extraction method on the molecular characteristics of AXs and
80 subsequent induction of NO/iNOS levels was investigated.

81 **Materials and Methods**

82 **Materials.** A sample of dried pentosan fraction (moisture content 5.9%) was kindly
83 provided by Henan Lianhua Monosodium Glutamate Group Co., Ltd (Xiangchen, Henan,
84 China). Pentopan Mono BG (2500 U/g), an endoxylanase product (EC 3.1.2.8, family 11

85 of glycosyl hydrolases) from *Thermomyces lanuginosus* (donor)/*Aspergillus oryzae*
86 (host), was supplied by Novozyme (Bagsvaerd, Denmark). The U937 cell line was
87 purchased from the Public Health England Culture Collections. LPS (lipopolysaccharides
88 of *Escherichia coli* serotype O111:B4) was purchased from Sigma-Aldrich (Gillingham,
89 UK). RPMI-1640 cell culture medium with L-glutamine was purchased from Lonza
90 (Verviers, Belgium). Human iNOS (116 µg/ml, Code: TP311819) was purchased from
91 Cambridge Bioscience (Cambridge, UK). The primary antibody, monoclonal iNOS
92 antibody (4E5) (1 mg/mL), was purchased from Novus Biologicals (Cambridge, UK). The
93 secondary antibody, the rabbit anti-mouse immunoglobulins/HRP (P0260), was
94 purchased from Dako (Glostrup, Denmark).

95 **Extraction of AXs.** The pentosan fraction of wheat flour was ground to a 0.5 mm
96 particle size using an Ultra Centrifugal Mill ZM 200 (RETSCH Ltd. United Kingdom).
97 Milled pentosan sample (30 g) was mixed with 200ml of distilled water using a hand
98 blender (800W, WSB800U) for 45 s prior to water or enzyme extraction. For the water
99 extraction process, the pentosan-water mixture was incubated in a shaking water bath at
100 40 °C for 2 h followed by centrifugation (6000g, 20 min) and collection of the

101 supernatant (containing extracted AX). For the enzymatic extraction process, three
102 extraction conditions (enzyme concentration, extraction time and temperature) were
103 considered according to those previously described for endoxylanase (P-BG) in the
104 preparation of wheat endosperm AXs (Li *et al.* 2013). The effect of endoxylanase
105 concentration (50, 100, 200, 300, 400 ppm, w/w), extraction time (2 h, 3 h, 4 h) and
106 temperature (20 °C, 30 °C and 40 °C) on extraction yield and structure of AXs from the
107 mixed pentosan sample were determined by the enzyme extraction procedure.

108 Following the extraction process, samples were centrifuged (6000g, 20 min), and the
109 supernatants were collected. Then the supernatants (150 mL) was added to 300 μ l
110 termamyl α -amylase (500 U/ml) at 90 °C to allow starch hydrolysis to occur. After 1 h,
111 the solution was cooled rapidly and adjusted to pH 7. One hundred μ l proteinase (1
112 mg/mL, ≥ 3 units/mg) was added to the solution and the mixture was incubated at 60 °C
113 for 1 h to remove unwanted protein. The sample was placed in a boiling water bath for
114 10 min to deactivate enzymes and then centrifuged at 6000g for 20 min. After
115 centrifugation, the supernatants were then precipitated according to the ethanol
116 precipitation process described by Zhang *et al.* (2016). The residue was then placed in

117 an oven overnight at 45 °C to dry and then milled using an analytical mill (IKA A11 Basic,
118 Guangzhou, China, 50/60Hz, 160W).

119 **Determination of AX extraction yields.** The determination method of AXs yield
120 was constructed using the methods described by Zhang *et al.* (2016) to evaluate the
121 xylose content of the raw material and extracted AX supernatants.

122 **Determination of monosaccharide compositions of isolated AXs.** The
123 composition assessment was performed as previously described by Zhang *et al.* (2016).
124 The mobile phase was HPLC grade water for the HPLC and isocratic elution was achieved
125 using a Shimadzu LC-10ADvp pump. Samples were analysed on SUPELCOGEL Pb (5 cm ×
126 4.6 mm) and Phenomenex ThermaSphere TS-130 columns combined with a JASCO RI-
127 2031 refractive index (RI) detector. All analyses were conducted in triplicate.

128 **Molecular weight distribution characterisation of extracted AXs.** Size exclusion
129 high-pressure liquid chromatography (SE-HPLC) with a RI detector (JASCO RI-2031,
130 Jasco Corporation, Tokyo, Japan) was used to determine the Mw and size distribution of
131 extracted AX samples using methods described by Zhang *et al.* (2016). The average
132 degree of polymerisation (avDP) was value of the apparent peak molecular mass divided

133 by the molecular mass of anhydropentose sugars (Courtin *et al.* 2008).

134 **Cell culture.** Complete cell culture medium was prepared using RPMI-1640 with L-
135 glutamine (Luna, Belgium), 10% foetal bovine serum (FBS) and 2% penicillin-
136 streptomycin (P/S). The human U937 monocyte cell line was grown in complete culture
137 medium under sterile conditions in a 37 °C incubator with 5% CO₂ in air atmosphere,
138 subculturing every 2 days to maintain high cell viability (≥ 90%). For experimental tests,
139 cultured U937 cells were centrifuged at 1000*g* for 10 min and re-suspended in RPMI-
140 1640 medium with L-glutamine and 10% FBS such that the density of cells was set at
141 1×10⁶ viable cells/ml.

142 **Polysaccharide medium preparations.** The extracted AX samples and LPS were
143 dissolved in the RPMI-1640 medium with 5% FBS overnight at 4 °C to allow the sample
144 to become fully hydrated prior to sterile filtration through a 0.45 μm sterile filter. The
145 LPS and solubilised AX samples were diluted in RPMI-1640 medium to yield a series of
146 typical concentrations (1, 5, 10, 50, 500 and 1000 μg/ml) (Zhang *et al.* 2016) for the
147 subsequent cell culture testing. The samples were stored at 4 °C prior to use.

148 **Cell viability and growth.** Cell growth and viability of U937 cells following

149 treatment with AX samples or LPS were assessed by cell counting and trypan blue
150 uptake. A 100 μL cell suspension at 1×10^6 viable cells/ml was pipetted into each well of
151 a 96-well microplate. The AX and LPS sterile medium preparations at three high
152 concentrations (50, 500 and 1000 $\mu\text{g}/\text{ml}$) were pre-warmed to 37 $^\circ\text{C}$ and 100 μL of each
153 concentration was added to six replicate wells of the microplate and mixed thoroughly.
154 After 24 h incubation (Ghoneum and Gollapudi 2003, Zhang *et al.* 2016), 40 μL from
155 each well was mixed with 40 μL of trypan blue (Sigma-Aldrich, UK) for 1 min prior to
156 analysis on a TC10 automated cell counter (Bio-Rad, UK). The number of blue stained
157 (non-viable) cells and unstained (viable) cells in each sample were counted.

158 **NO stimulation.** The NO assay was conducted as previously described by (Zhang *et*
159 *al.* 2016). Fifty μl of U937 cells at 1×10^6 viable cells/ml was added to a 96-well
160 microplate prior to adding 50 μl of AX or LPS sample to replicate wells. Replicate
161 untreated controls were prepared by adding 50 μl medium with 50 μl U937 cells at
162 1×10^6 viable cells/ml to wells. Background levels of nitrite and/or interference from
163 nitrate present in AX samples were internally controlled for within the assay by taking in
164 account the direct activity of AX samples in replicate wells containing 50 μl medium and

165 50 μ l of diluted sterile AX sample in the absence of U937 cells. All experimental samples
166 were evaluated in triplicate with appropriate adjustments for background nitrite/nitrate
167 levels. The microplate was incubated (37 °C, 5% CO₂) for 24 hours before mixing 50 μ l
168 component A of the Griess' reagent to each well for 10 minutes at room temperature.
169 Griess' reagent was made up with two components. Component A consisted of equal
170 amounts by volume of 37.5 mmol/L sulphanilamide in deionized water and 6.5 mol/L
171 HCl. Component B was 12.5 mmol/L N-1-naphthylethylenediamine dihydrochloride
172 (NEED) in deionized water. A further 50 μ l component B of the Griess' reagent was added
173 to each well, mixing well and then incubating at 4°C for 20 minutes. The absorbance of
174 each well was measured at 540nm using a microplate reader (Synergy HTX Multi-Mode
175 Reader, Biotek, UK).

176 **Determination of iNOS Levels.** An immunoblot assay was used to determine the
177 iNOS level in cell lysates according to previously described methodologies (Bloch *et al.*
178 1999). An equal volume (5mL) of AX treatment, LPS positive control (at 50 μ g/mL) or
179 untreated media control (RPMI-1640 with L-glutamine and 5% FBS) was incubated for
180 24 h with 5mL cultured U937 cells set at 2.0×10^6 viable cells/ml. Samples were

181 centrifuged (1000g for 10 min) and resuspended in the fresh medium at a density of
182 2×10^6 viable cells /mL. A 9ml aliquot of each sample was centrifuged at 1000g for 10
183 min and the supernatant discarded. The cell pellet was kept on ice and 150 μ l ice-cold
184 lysis buffer (0.1 M Tris-HCl and 1 mM EDTA in deionized water; pH 7.8) was added to
185 each cell pellet. The samples underwent a repeated (three times) rapid freeze/thaw
186 process to lyse the cells by placing in a freezer (-80 °C) for 15 min followed by rapid
187 thawing in a 37 °C water bath until just thawed, with vortex mixing for 10 s in between
188 each freeze/thaw cycle. Samples were repeatedly (10 times) placed in a sonication bath
189 (5510E-DTH, 490W, 50/60Hz, Branson, Danbury, USA) for 10 s, followed by vortex
190 mixing in between each sonication step. The samples were centrifuged at 10,000g for 10
191 min and supernatants (cell lysates) were collected.

192 A 5 μ l aliquot of each cell lysate was added to 500 μ l ice-cold lysis buffer (1:100
193 dilution). Human iNOS enzyme (116 μ g/mL) was diluted in the iNOS standard buffer
194 (10% glycerol, 100mM glycine and 25mM Tris-HCl in deionized water) to provide a set
195 of iNOS standards at 116, 58, 29, 14.5 and 11.6 μ g/mL. The cell lysates and iNOS
196 standards were placed as 5 μ l immunoblots on NC 45 nitrocellulose membrane (Serva

197 Electrophoresis GmbH, Heidelberg, Germany), and 5 μ l BSA solution (1 mg/ml BSA in
198 deionized water) was used as a negative control (absence of iNOS protein). The
199 membrane was incubated in a 1:1000 dilution of monoclonal iNOS primary antibody
200 (4E5) overnight (\leq 20h) at 4°C with shaking at 60rpm.

201 The membrane was washed five times for 5 min using TBS buffer before incubating
202 with the rabbit anti-mouse immunoglobulins/HRP secondary antibody solution (1:1000
203 dilution) at room temperature for 1 h with shaking at 60rpm. The membrane was
204 washed five times for 5 min in TBS buffer and then 1 mL chemiluminescent detection
205 reagent (Biological Industries (BI), Lichfield, UK) was gently distributed across the
206 membrane and left to stand for 1 min in a dark room. Images of the membrane were
207 then captured using a G:Box (Chemi HR16, Syngene, Cambridge, UK) and Image J
208 software (National Institute of Health, USA) was used to quantify the levels of iNOS using
209 the iNOS standards. The iNOS level was determined from three replicate experiments.

210 **Statistical Analysis.** Experiments, unless otherwise stated, were performed in
211 triplicate and analyzed by one-way ANOVA followed by a posthoc Tukey test. A value of p
212 < 0.05 was considered statistical significance in all cases. Data were expressed as mean \pm

213 standard error of the mean (SEM) unless stated otherwise.

214 **Results and Discussion**

215 **Extraction of AXs from the pentosan fraction of wheat flour.** The original AX
216 content of the wheat flour pentosan was determined as $15.79 \pm 0.46\%$ (dry basis).
217 Compared with water extraction (Table 1), the extraction yield of AXs significantly
218 increased ($P < 0.05$) from 7.54% to 12.83% with increasing enzyme (endoxy lanase, P-
219 BG) concentration (0 to 400 ppm). In particular, significant increases ($P < 0.05$) in
220 extraction yield positively correlated ($r = 0.98$) with increased enzyme concentration
221 within the range of 50 ppm to 200 ppm. Higher enzyme concentrations, from 200ppm to
222 400ppm, did not significantly increase the yield further ($P > 0.05$), indicating that
223 maximum extraction condition was achieved, with no benefit in increasing the enzyme
224 concentration any further beyond this range. The treatment temperature also showed a
225 significant effect on the extraction yield of AXs. Temperatures of 30 °C - 40 °C showed
226 higher AX extraction yield than 20 °C ($P < 0.05$) with an enzyme concentration of 200
227 ppm, a 2 h incubation and pH 4.5. Moreover, with an enzyme concentration of 400 ppm
228 at 40 °C for 2 h, recovery of AXs from the pentosan fraction reached the highest recovery

229 level (81.25% of total AX content) identified in the study. The increased extraction yield
230 upon enzyme treatment is likely in large part due to endoxylanases cleaving internal β -
231 (1,4)-linkages in the xylan backbone and rendering a portion of water un-extractable
232 AXs (WUAXs) soluble and extractable (Andersson *et al.* 2003). This means that a fraction
233 of the WUAXs in the cell wall of the pentosan will be released into solution, resulting in
234 increased extraction yield.

235 **Monosaccharide compositions and branch degree analysis of AXs.** The enzyme
236 extracted AXs samples (E-WEAXs) had a higher A/X ratio of 0.83 (Table S1) than water
237 extracted AXs (WEAXs) of 0.48, with A/X increasing linearly as the enzyme
238 concentration increased from 0 ppm to 400 ppm ($R^2 = 0.958$). The A/X ratio represents
239 the degree of branching of AXs, which is an indicator of the relative proportions of the
240 substituted xylose residues in xylan chains (Izydorczyk and Biliaderis 2007). The degree
241 of substitution plays a key role in the solubility of AXs. Less arabinose substitutes
242 resulted in a lower solubility of AXs in water (Zhang *et al.* 2014), which the reason was
243 the low A/X substitution fraction enhance aggregation of unsubstituted regions of the
244 AXs stabilised by hydrogen bonds, which may result in an increase in viscosity or

245 precipitation of polymer chains (Izydorczyk and Biliaderis 2007). Therefore, the results
246 suggest AXs extracted from the pentosan fraction using the enzymatic treatments
247 contained more substituted xylose residues and higher solubility.

248 **Molecular characterisation of AXs.** The overall Mw distribution of AXs ranged
249 from 159 Da to 794 KDa and it was divided into four ranges (Table S1). Around 79% of
250 WEAXs were mainly in the larger Mw range of 10 KDa to 794 KDa whereas 81-89% of E-
251 WEAXs were in the smaller Mw range of 1 KDa to 100 KDa. The Mw distribution curve of
252 the E-WEAXs (Figure 1) contains two main peaks; the major one with Mw of 12.22 KDa
253 ($\log_{10}M_w \approx 4.1$, $avDP = 93$), and the lesser one with Mw of 3.72 KDa ($\log_{10}M_w \approx 3.6$,
254 $avDP = 28$). However, the Mw distribution curve for the WEAX sample comprises mainly
255 a single peak with Mw of 501.19 KDa ($\log_{10}M_w \approx 5.7$, $avDP = 3797$). In addition, the Mw
256 distribution (Fig. 1) shows the Mw peak at around 3.72 KDa ($\log_{10}M_w \approx 3.6$) progressing
257 enlarged as the concentration of enzyme increased from 50 ppm to 400 ppm. According
258 to previous studies, endoxylanase attacks the β -1, 4 linked D-xylopyranosyl backbone
259 and breaks down xylan chains, thus reducing the molecular weight of AXs during
260 enzymatic extraction (Izydorczyk and Biliaderis 2007). Zhang *et al.* (2014) showed that

261 the Mw of AXs varies depending on the extraction and treatment methods used.
262 Endoxylanase treatment appeared to be one of the most effective methods for modifying
263 AXs molecular structure, resulting in AXs with low Mw distribution. Furthermore, the
264 Mw has been indicated as a crucial factor influencing the physicochemical properties in
265 solution. Wheat AXs with low Mw exhibited less intrinsic viscosities and weak elastic
266 properties when in solution (Izydorczyk and Biliaderis 2007).

267 **Effects of AXs on the growth and viability of U937 cells.** In order to investigate
268 the possible relationship between the immunomodulatory activity and molecular
269 structure of AXs, WEAX and E-WEAX with significantly different Mw distributions and
270 monosaccharide compositions, were extracted with an enzyme concentration of 400
271 ppm for *in vitro* studies.

272 The total cell counts of U937 macrophages treated with high concentrations of AXs
273 (50, 500, 1000 $\mu\text{g/ml}$) were not significantly different ($P > 0.05$) compared to the
274 untreated control (Table 2). WEAX and E-WEAX did not induce a stimulatory effect on
275 the growth of U937 cells over a period of 24 h. In addition, the viability of cells following
276 each AX treatment was typically around 90%, which was not significantly different ($P >$

277 0.05) to untreated control cells, suggesting AX samples had no effect on U937 cell
278 survival over a 24 h period. However, the total count of U937 cells was significantly ($P <$
279 0.05) reduced after treatment with 500 and 1000 $\mu\text{g}/\text{ml}$ LPS compared with the
280 untreated control (Table 2). This is in concordance with previous studies indicating that
281 LPS inhibits and blocks macrophage proliferation in a dose-dependent manner (Vairo *et*
282 *al.* 1992, Vadiveloo *et al.* 1996, Muller-Decker *et al.* 2005). The inhibitory effect of LPS on
283 cell proliferation is tightly regulated through a complex network of cytokines. For
284 example, Vadiveloo *et al.* (2001) found that bacterial LPS had an inhibitory effect on cell
285 proliferation in mouse marrow-derived macrophages. They found LPS inhibited the
286 expression of cyclin D1, which is an essential protein for proliferation in many cell types.
287 Botanical polysaccharides extracted from plants have received considerable attention in
288 bioscience due to their wide immunomodulatory activities and low toxicity (Schepetkin
289 and Quinn 2006). Compared with LPS, the present study indicated that the AX samples
290 have no inhibitory effects on the viability and growth of human U937 macrophages, even
291 at high concentrations of 1000 $\mu\text{g}/\text{ml}$.

292 **Effects of AXs on NO production by U937 cells.** NO production by U937 cells

293 following treatment with WEAX, E-WEAX or LPS over the concentration range of 1 to
294 500 $\mu\text{g}/\text{ml}$ was determined (Table 3). The LPS positive control, significantly stimulated
295 ($P < 0.05$) NO secretion per million viable cells at all concentrations (1 to 500 $\mu\text{g}/\text{ml}$)
296 compared to the untreated control. Although significant changes in NO were not
297 detected across every single successive LPS concentration, overall the NO generated by
298 LPS significantly ($P < 0.05$) increased as LPS concentration increased from 0 to 500
299 $\mu\text{g}/\text{ml}$. All concentrations of WEAX and E-WEAX tested also significantly elevated ($P <$
300 0.05) NO production by U937 cells compared with the untreated control. NO levels per
301 million viable cells significantly increased in a dose-dependent manner as the
302 concentration of E-WEAX increased by 2 or more incremental concentration steps (from
303 1 to 10 $\mu\text{g}/\text{ml}$ and 5 to 50 $\mu\text{g}/\text{ml}$), before reaching a maximum of $61.8 \pm 2.7 \mu\text{M}$ following
304 treatment with 50 $\mu\text{g}/\text{ml}$ E-WEAX. In contrast, NO stimulation by WEAX in the
305 concentration range of 10 to 50 $\mu\text{g}/\text{ml}$ was substantially more modest compared to that
306 produced by similar concentrations of E-WEAX. The highest NO level produced was 53.4
307 μM per million viable cells after treatment with 500 $\mu\text{g}/\text{ml}$ WEAX, but this was still
308 significantly increased ($P < 0.05$) in a dose-dependent manner compared to NO levels

309 generated by lower WEAX concentrations in the range 1 to 10 $\mu\text{g}/\text{ml}$. Thus, the optimal
310 dose of E-WEAX for maximum NO production was found to be $< 500 \mu\text{g}/\text{ml}$ in this study
311 whereas WEAX probably had an optimum dose somewhere above $500 \mu\text{g}/\text{ml}$. Although
312 the peak NO secretion for the WEAX treatment may not have been reached in the assay,
313 the findings suggest the maximum NO secretion was being approached and was
314 substantially below that of E-WEAX. These comparisons show that there are obvious
315 differences between E-WEAX and WEAX treatments in relation to NO stimulation, with
316 WEAX generally having weaker NO stimulation than E-WEAX. This is consistent with the
317 NO stimulatory activities of corn bran AXs with low and large Mw in U937 cells (Zhang *et*
318 *al.* 2016).

319 One of main structural differences between the two types of AX samples was in the
320 low Mw range of 1-10 KDa. The E-WEAX contained a higher portion of AX with lower
321 avDP in this small Mw range compared with WEAX. In addition, E-WEAX presented a
322 higher A/X ratio (0.83) compared to WEAX (0.48). Thus, the large difference in NO
323 stimulatory activity between the two AX samples may be associated with the difference
324 in the low 1-10kDa Mw fractions and A/X ratio.

325 **Effects of AX treatments on iNOS levels in U937 cells.** In order to obtain a better
326 understanding of AX modulation of NO production, the effect of WEAX and E-WEAX on
327 iNOS levels was determined in human U937 monocytes. Both WEAX and E-WEAX
328 significantly elevated iNOS levels in U937 cells (Figure 2A) after 24h compared with the
329 untreated control ($P < 0.05$), mirroring the elevation detected in NO production. E-WEAX
330 and WEAX resulted in a 2.5 and 2.0 fold increase in iNOS level per million viable U937
331 cells respectively compared with the untreated control (Figure 2B). In addition, the
332 amount of iNOS following treatment with E-WEAX was significantly higher than with
333 WEAX ($P < 0.05$). Similarly, the LPS positive control significantly increased iNOS levels
334 compared to untreated control ($P < 0.05$). The stimulatory effect of AXs on iNOS was
335 highly correlated with their stimulatory activity on NO production. Thus, the findings
336 suggest the increased NO production by AXs is probably due, at least in part, by elevated
337 levels of iNOS in U937 cells. This is in agreement with the previous reports that show
338 both iNOS mRNA and protein levels in macrophages are induced by cytokines (such as
339 IFN- γ and TNF- α) and microbial polysaccharides such as LPS (Bogdan 2000). More
340 recently a study found that polysaccharides from *Dendrobium officinale* were able to

341 increase iNOS expression and NO production in RAW 264.7 cells. They indicated that the
342 stimulatory ability of *D. officinale* on iNOS expression was associated with the disruption
343 of I κ B α /NF- κ B complexes, leading to the activation of NF- κ B (Cai *et al.* 2015). Thus, AXs
344 may stimulate NO production in U937 cells through the iNOS pathway. Moreover, the
345 immunoblots showed that E-WEAX (50 μ g/mL) had a higher stimulatory effect ($P <$
346 0.05) on iNOS level (42.4 ± 3.8 μ g/mL per million viable cells) compared to the effect of
347 WEAX (33.5 ± 1.5 μ g/mL per million viable cells) at the same concentration. The
348 difference in stimulatory effect between E-WEAX and WEAX on iNOS induction overlaps
349 with their significantly different stimulatory activity on NO production.

350 The Mw distribution of AX is considered to be a significant determinant of their
351 immune-modulatory activity. Physicochemical properties of AXs in solution including tertiary
352 conformation, solubility, viscosity and elastic properties depend on their molecular weight
353 and degree of branching (Izydorczyk and Biliaderis 2007). For other cereal polysaccharide,
354 such as Beta-glucan, molecular size and solubility have already been confirmed to have a
355 substantial effect on Dectin-1 receptor activation, which is associated with immune-
356 modulating activities of Beta-glucan such as increased level of iNOS, IL-12, TNF- α , IL-1 β and

357 IL-6 (Zhang *et al.* 2015, Liu *et al.* 2015). Recently, wheat AX was reported to activate the
358 Dectin-1 receptor in the HEK-Null1 Dectin-1A and B cell lines (Sahasrabudhe *et al.*
359 2016). Therefore, it is reasonable to conclude that molecular structure, combined with these
360 physicochemical properties of AX may confer receptor activation that result in different
361 stimulatory effects on iNOS expression in macrophage and subsequent NO production.

362 **4. Conclusion**

363 Dietary intervention of foods and food-derived substances with immune-modulating
364 activities is widely studied and considered a potential way of mediating immune functions to
365 reduce the risk of infection or cancer (Zhang *et al.* 2015, Mendis *et al.* 2016). In this study,
366 an enzymatic method was optimized to efficiently extract high yields (86%) of AXs with
367 a high proportion of low MW (3.72 KDa) material and a high degree of branching (A/X =
368 0.83) from wheat flour pentosan. AX extracts significantly elevated NO secretion by the
369 U937 cells compared with the untreated control ($P < 0.05$), suggesting the AXs have potential
370 immunomodulation properties for improving immune function and reducing the risk of
371 infection. Analysis of the relationship between the molecular structures and the
372 immunomodulatory activity of AX samples suggests that enzyme-modified AXs, that

373 have a much higher proportion of lower Mw AXs and higher A/X ratio than the non-
374 enzyme treated AXs, stimulate higher levels of NO production. The iNOS data suggest that
375 stimulation of NO synthesis by AXs is closely mirrored iNOS expression in U937 cells. This is
376 an exciting area for future research, the findings elucidating the precise mechanisms
377 through which the molecular structure of AXs may modulate immunomodulatory
378 activity. Further experimental work is required to identify the AX receptor(s) on
379 macrophages and determine their interaction with iNOS expression.

380 **Acknowledgements**

381 We also would like to thank the technician team, Phil Evans, Roya Yazdanian, Glenn
382 Ferris and a PhD candidate, Nicola Hall for their support in the experimental work.

383 **Funding**

384 The authors are grateful for funding support from Department of Food, Nutrition and
385 Hospitality of Manchester Metropolitan University (L-30073).

386 **Notes**

387 The authors declare no competing financial interest.

388 **References**

- 389 Andersson, R., Eliasson, C., Selenare, M., Kamal-Eldin, A. and Aman, P. (2003) 'Effect of
390 endo-xylanase-containing enzyme preparations and laccase on the solubility of rye
391 bran arabinoxylan', *Journal of the Science of Food and Agriculture*, 83(7), 617-623.
392
- 393 Bloch , W., Fleischmann , B. K., Lorke , D. E., Andressen , C., Hops , B., Hescheler , J. and K.,
394 A. (1999) 'Nitric oxide synthase expression and role during cardiomyogenesis',
395 *Cardiovascular Research*, 43 (3), 675-684.
396
- 397 Bogdan, C. (2000) 'The function of nitric oxide in the immune system' in Mayer, B., ed.
398 *Handbook of Experimental Pharmacology*, Heidelberg: Springer, 443-492
399
- 400 Cai, H., Huang, X., Nie, S., Xie, M., Phillips, G. O. and W., C. S. (2015) 'Study on *Dendrobium*
401 *officinale* O-acetyl-glucomannan (Dendronan®): Part III-Immunomodulatory
402 activity in vitro.', *Bioactive Carbohydrates and Dietary Fibre*, 5(2), 99-105.
403
- 404 Choi, J. Y., Paik, D. J., Kwon, D. Y. and Park, Y. (2014) 'Dietary supplementation with rice
405 bran fermented with *Lentinus edodes* increases interferon-gamma activity
406 without causing adverse effects: a randomized, double-blind, placebo-controlled,
407 parallel-group study', *Nutrition Journal*, 13(1), 35.
408
- 409 Courtin, C. M., Swennen, K., Broekaert, W. F., Swennen, Q. and Buyse, J. (2008) 'Effects of
410 dietary inclusion of xylooligo-saccharides, arabinoxyloligosaccharides and
411 soluble arabinoxylan on the microbial composition of caecal contents of chickens',
412 *Journal of the Science of Food and Agriculture.*, 88(14), 2517-2522.
413
- 414 Escarnot, E., Aguedo, M. and Paquot, M. (2012) 'Enzymatic hydrolysis of arabinoxylans
415 from spelt bran and hull', *Journal of Cereal Science*, 55(2), 243-253.
416
- 417 Fan, L., Ma, S., Wang, X. and Zheng, X. (2016) 'Improvement of Chinese noodle quality by
418 supplementation with arabinoxylans from wheat bran', *International Journal of*

419 *Food Science & Technology*, 51(3), 602-608.

420

421 Ghoneum, M. and Gollapudi, S. (2003) 'Modified arabinoxylan rice bran (MGN-3/Biobran)

422 sensitizes human T cell leukemia cells to death receptor (CD95)-induced

423 apoptosis', *Cancer Letters*, 201(1), 41-9.

424

425 Ghoneum, M. and Matsuura, M. (2004) 'Augmentation of macrophage phagocytosis by

426 modified arabinoxylan rice bran (MGN-3/biobran)', *International Journal of*

427 *Immunopathology and Pharmacology*, 17(3), 283-92.

428

429 Izydorczyk, M. S. and Biliaderis, C. G. (2007) 'Arabinoxylans: Technologically and

430 nutritionally functional plant polysaccharides' in Biliaderis, C. G. and Izydorczyk,

431 M. S., eds., *Functional Food Carbohydrates*, Boca Raton: CRC Press, 249-290.

432

433 Lechner, M., Lirk, P. and Rieder, J. (2005) 'Inducible nitric oxide synthase (iNOS) in tumor

434 biology: the two sides of the same coin', *Seminars in cancer biology*, 15(4), 277-89.

435

436 Li, L., Ma, S., Fan, L., Zhang, C., Pu, X., Zheng, X. and Wang, X. (2016) 'The influence of

437 ultrasonic modification on arabinoxylans properties obtained from wheat bran',

438 *International Journal of Food Science & Technology*, 51(11), 2338-2344.

439

440 Li, W., Hu, H., Wang, Q. and Brennan, C. S. (2013) 'Molecular Features of Wheat Endosperm

441 Arabinoxylan Inclusion in Functional Bread', *Foods*, 2(2), 225-237.

442

443 Liu, M., Luo, F., Ding, C., Albeituni, S., Hu, X., Ma, Y., Cai, Y., McNally, L., Sanders, M. A., Jain,

444 D., Kloecker, G., Bousamra, M., 2nd, Zhang, H. G., Higashi, R. M., Lane, A. N., Fan, T. W.

445 and Yan, J. (2015) 'Dectin-1 Activation by a Natural Product beta-Glucan Converts

446 Immunosuppressive Macrophages into an M1-like Phenotype', *The Journal of*

447 *Immunology*, 195(10), 5055-65.

448

449 Mendis, M., Leclerc, E. and Simsek, S. (2016) 'Arabinoxylans, gut microbiota and immunity',

450 *Carbohydrate Polymers*, 139, 159-66.

451

452 Muller-Decker, K., Manegold, G., Butz, H., Hinz, D. E., Huttner, D., Richter, K. H., Tremmel, M.,
453 Weissflog, R. and Marks, F. (2005) 'Inhibition of cell proliferation by bacterial
454 lipopolysaccharides in TLR4-positive epithelial cells: independence of nitric oxide
455 and cytokine release', *Journal of Investigative Dermatology*, 124(3), 553-61.
456

457 Nagata, J., Higashiuesato, Y., Maeda, G., Chinen, I., Saito, M., Iwabuchi, K. and Onoe, K. (2001)
458 'Effects of water-soluble hemicellulose from soybean hull on serum antibody levels
459 and activation of macrophages in rats', *Journal of Agricultural and Food Chemistry*,
460 49(10), 4965-70.
461

462 Sahasrabudhe, N. M., Schols, H. A., Faas, M. M. and de Vos, P. (2016) 'Arabinoxylan activates
463 Dectin-1 and modulates particulate beta-glucan-induced Dectin-1 activation',
464 *Molecular Nutrition & Food Research*, 60(2), 458-67.
465

466 Schepetkin, I. A. and Quinn, M. T. (2006) 'Botanical polysaccharides: macrophage
467 immunomodulation and therapeutic potential', *International*
468 *Immunopharmacology*, 6(3), 317-33.
469

470 Smith, P. D., Smythies, L. E., Shen, R., Greenwell-Wild, T., Gliozzi, M. and Wahl, S. M. (2011)
471 'Intestinal macrophages and response to microbial encroachment', *Mucosal*
472 *Immunology*, 4(1), 31-42.
473

474 Vadiveloo, P. K., Keramidaris, E., Morrison, W. A. and Stewart, A. G. (2001)
475 'Lipopolysaccharide-induced cell cycle arrest in macrophages occurs
476 independently of nitric oxide synthase II induction', *Biochimica et Biophysica Acta*
477 *(BBA)-Molecular Cell Research*, 1539(1), 140-6.
478

479 Vadiveloo, P. K., Vairo, G., Novak, U., Royston, A. K., Whitty, G., Filonzi, E. L., Cragoe, E. J., Jr.
480 and Hamilton, J. A. (1996) 'Differential regulation of cell cycle machinery by various
481 antiproliferative agents is linked to macrophage arrest at distinct G1 checkpoints',
482 *Oncogene*, 13(3), 599-608.
483

484 Vairo, G., Royston, A. K. and Hamilton, J. A. (1992) 'Biochemical events accompanying

485 macrophage activation and the inhibition of colony-stimulating factor-1-induced
486 macrophage proliferation by tumor necrosis factor-alpha, interferon-gamma, and
487 lipopolysaccharide', *Journal of Cellular Physiology*, 151(3), 630-41.
488

489 Van Craeyveld, V., Dornez, E., Holopainen, U., Selinheimo, E., Poutanen, K., Delcour, J. A. and
490 Courtin, C. M. (2010) 'Wheat bran AX properties and choice of xylanase affect
491 enzymic production of wheat bran-derived arabinoxylanoligosaccharides', *Cereal*
492 *Chemistry*, 87(4), 283-291.
493

494 Zhang, S., Li, W., Smith, C. J. and Musa, H. (2015) 'Cereal-derived arabinoxylans as
495 biological response modifiers: extraction, molecular features, and immune-
496 stimulating properties', *Critical Reviews in Food Science and Nutrition*, 55(8), 1033-
497 50.
498

499 Zhang, Z., Smith, C. and Li, W. (2014) 'Extraction and modification technology of
500 arabinoxylans from cereal by-products: A critical review', *Food Research*
501 *International*, 65, 423-436.
502

503 Zhang, Z., Smith, C., Li, W. and Ashworth, J. (2016) 'Characterization of Nitric Oxide
504 Modulatory Activities of Alkaline-Extracted and Enzymatic-Modified
505 Arabinoxylans from Corn Bran in Cultured Human Monocytes', *Journal of*
506 *Agricultural and Food Chemistry*, 64(43), 8128-8137.
507

508 Zhou, S., Liu, X., Guo, Y., Wang, Q., Peng, D. and Cao, L. (2010) 'Comparison of the
509 immunological activities of arabinoxylans from wheat bran with alkali and
510 xylanase-aided extraction', *Carbohydrate Polymers*, 81(4), 784-789.
511
512

513 **List of Tables**

514 **Table 1.** Extraction yield (dry basis) of arabinoxylans (AXs) under different
515 enzymatic conditions

516 **Table 2.** Effects of arabinoxylans (AXs) and lipopolysaccharides (LPS) on the
517 growth and viability of U937 cells

518 **Table 3.** NO production per million viable cells by U937 cells following treatment
519 with water extracted arabinoxylan (WEAX), enzyme extracted arabinoxylan (E-
520 WEAX) or lipopolysaccharides (LPS)

521 **List of Figures**

522 **Figure 1.** The molecular weight distribution of enzyme extracted arabinoxylans
523 (E-WEAXs) following various enzyme treatments and water extracted
524 arabinoxylans as a Control

525 **Figure 2.** Effects of AXs and LPS on iNOS levels in U937 cells detected by
526 immunoblot assay **(A):** *The blots in the first line are iNOS standards (Dilution of*
527 *stock human iNOS enzyme at 116µg/ml) and a blank control standard (containing*
528 *BSA but no iNOS protein). The blots in the second line are derived from U937 cells*
529 *incubated for 24h with WEAX, E-WEAX or LPS (50µg/ml) treatment. (B): The iNOS*
530 *levels from the U937 cells were quantified by densitometry analysis and human iNOS*
531 *protein standards (Cambridge Bioscience, UK) of known concentration; The mean*
532 *iNOS concentration (µg/ml) in the cell lysates is presented as the mean + standard*
533 *error of the mean (SEM) of triplicate experiments. The symbol * indicate results that*
534 *are significantly different ($P < 0.05$) and the dotted line '---' indicates the iNOS level*
535 *of control cells.*

536 **Table 1.** Extraction yield (dry basis) of arabinoxylans (AXs) under different
 537 enzymatic extraction conditions

Treatment conditions		Extraction yield of AXs	AX content of Raw material
Treatment	20 °C	11.12±0.39% ^b	
Temperature	30 °C	12.97±0.34% ^a	
	40 °C	12.73±0.53% ^a	
<i>Under pH 4.5, 200 ppm endoxylanase for 2 h in all cases</i>			
Treatment	2 h	12.72±0.54% ^a	
Time	3 h	12.21±0.34% ^a	
	4 h	12.44±0.34% ^a	
<i>Under pH 4.5, 200 ppm endoxylanase at 40 °C in all cases</i>			15.79±0.46%
Enzyme	50 ppm	10.31±0.26% ^b	
Concentration	100 ppm	10.71±0.55% ^b	
	200 ppm	12.70±0.55% ^a	
	300 ppm	12.75±0.40% ^a	
	400 ppm	12.83±0.35% ^a	
<i>Under pH 4.5 at 40 °C for 2 h in all cases</i>			
Control	Water extraction	7.54±0.47% ^c	

538 *Extracted AXs using the different enzyme concentrations (50 ppm to 400 ppm), treatment temperatures*
 539 *(20 °C to 40 °C) and extraction times (2 h to 4 h) were investigated in terms of yield and AX content. The*
 540 *control indicates water extractable AX (WEAX) that lacked enzymatic treatment. The extraction yields*
 541 *are presented as mean ± standard deviation and experiments were conducted in triplicate. Dissimilar*
 542 *superscripts (^{a,b,c}) highlight significantly different AX extraction yields among the various extraction*
 543 *treatments (P < 0.05).*

544 **Table 2.** Effects of arabinoxylans (AXs) and lipopolysaccharides (LPS) on the growth
 545 and viability of U937 cells

Sample	Concentration of AXs and LPS ($\mu\text{g/ml}$)						Untreated Control	
	50		500		1000		Total count	Viability
	Total count	Viability	Total count	Viability	Total count	Viability		
LPS	1.18 \pm 0.029	92.63%	0.92 \pm 0.05*	90.21%	0.91 \pm 0.024*	88.15%	1.17 \pm 0.022	90.90%
E-	1.21 \pm 0.021	90.60%	1.22 \pm 0.046	90.09%	1.23 \pm 0.032	90.70%		
WEAX								
WEAX	1.25 \pm 0.026	90.72%	1.23 \pm 0.016	90.48%	1.24 \pm 0.037	89.60%		

546 *The total count ($\times 10^6$ cells) indicates the number of total (viable and non-viable) U937 cells after various*
 547 *AX treatments for 24 h. The viability (%) was calculated as the viable cell count/total cell count \times 100.*
 548 *The total cell count and viability after treatment with AXs or LPS were compared with the untreated*
 549 *control by one way ANOVA, with the symbol * highlighting a significant difference ($P < 0.05$). Total cell*
 550 *counts are presented as mean \pm standard error of six replicate samples.*


551 **Table 3.** NO production per million viable cells by U937 cells following treatment
 552 with water extracted arabinoxylan (WEAX), enzyme extracted arabinoxylan (E-WEAX)
 553 or lipopolysaccharides (LPS)

Samples	Concentration of AXs and LPS ($\mu\text{g/ml}$)					
	0	1	5	10	50	500
LPS *		63.0 \pm 2.1	64.5 \pm 0.9	64.8 \pm 1.9	65.7 \pm 1.6	70.8 \pm 0.9
E-WEAX *		51.9 \pm 3.5 \$	51.1 \pm 2.5 \$	58.9 \pm 2.5 \$@	61.8 \pm 2.7 @	51.5 \pm 1.5 \$
WEAX *		48.6 \pm 0.9 \$	48.0 \pm 0.4 \$	48.4 \pm 3.3 \$	51.6 \pm 2.6 \$	53.4 \pm 2.7 \$
Control	43.0 \pm 0.4					

indicates significant change in NO secretion (P < 0.05) between the two indicated concentrations of samples.
 @ indicates significant difference (P < 0.05) in NO secretion between treatment with E-WEAX and treatment with WEAX at the same concentration.
 \$ indicates significant (P < 0.05) difference in NO secretion between E-WEAX or WEAX treatment and LPS treatment at the same concentration.

554 *The NO₂ concentration (μM), presented as mean \pm standard error of triplicate samples, is a measure of*
 555 *NO production by U937 cells. The symbol * indicates significant increase (P < 0.05) in NO secretion*
 556 *following AX treatment at **all concentrations tested** compared to the untreated control. The symbol #*
 557 *indicates a significant change in NO secretion (P < 0.05) the two indicated concentrations of samples. The*
 558 *symbol @ indicates significant difference (P < 0.05) in NO secretion between treatment with E-WEAX and*
 559 *treatment with WEAX at the same concentration. The symbol \$ indicates significant (P < 0.05) difference*
 560 *in NO secretion between E-WEAX or WEAX treatment and LPS treatment at the same concentration.*

561 **Graphical Abstract**



562


563

564

565

566

567 **Figure 1**



568

569

570

571

572

573


574

575


576 **Figure 2**

577

A.



B.



578

579

580

581

582

583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607

Table S1. The structural characteristics of arabinoxylan (AX) samples obtained under different enzyme extraction conditions.

Treatment conditions		Monosaccharides compositions of AXs ^a					Mw distributions of AXs ^c			
		Ara(%)	Xyl(%)	Glc(%)	Gal(%)	A/X ^b	Range 1: 10 ⁵ -10 ^{5.9} Da	Range 2: 10 ⁴ -10 ⁵ Da	Range 3: 10 ³ -10 ⁴ Da	Range 4: 10 ^{2.2} -10 ³ Da
Control	Water	26.13±1.01	53.96 ±1.49 ^y	10.62±2.04 ^x	9.29 ±1.26 ^x	0.48	46.46%	32.06%	19.11%	2.37%
Enzyme	50 ppm	28.15±1.34	49.65±1.22 ^y	11.92±0.95 ^x	10.28±1.32 ^x	0.57	15.27%	45.54%	35.42%	3.77%
Concentration ^d	100 ppm	29.93±0.69	47.92±2.02 ^y	11.42±0.83 ^x	10.74±1.23 ^x	0.62	9.26%	40.29%	46.72%	3.72%
	200 ppm	26.77±1.23	37.13±0.76 ^x	20.3±0.86 ^y	15.81±0.32 ^y	0.72	7.17%	40.62%	46.82%	5.39%
	300 ppm	27.11±0.76	35.37±2.92 ^y	21.32±1.03 ^y	16.2±1.43 ^y	0.77	6.47%	40.09%	48.88%	4.56%
	400 ppm	28.74±1.77	34.51±0.34 ^y	21.85±2.22 ^y	14.9±2.32 ^y	0.83	5.75%	39.89%	49.51%	4.85%
Treatment	2 h	26.88±0.83	37.21±0.48	20.3±0.63	15.61±0.78	0.72	7.33%	40.18%	47.38%	5.11%
Time ^e	3 h	27.52±0.34	38.22±1.32	19.84±0.63	14.42±0.79	0.72	7.48%	40.30%	47.04%	5.18%
	4 h	26.72±0.54	37.81±0.86	20.01±0.89	15.46±1.46	0.71	7.13%	40.45%	46.93%	5.49%
Treatment	20 °C	27.11±1.82	39.04±1.64	18.47±1.33	15.38±0.49	0.70	7.15%	40.52%	46.87%	5.46%
Temperature ^f	30 °C	28.15±1.67	39.19±0.76	18.01±2.55	14.65±0.64	0.72	7.05%	40.69%	46.79%	5.47%
	40 °C	26.67±1.05	37.22±0.35	20.34±0.50	15.77±0.44	0.72	7.23%	40.45%	46.75%	5.57%

a: The proportion of each monosaccharide in the AX sample is presented as mean + standard deviation and all experiments were conducted in triplicate. b: A/X represents the composition ratio of arabinose to xylose. c: The distribution (%) of AXs in different Mw ranges were analysed using the LC Data Analysis (SHIMADZU Corporation). d: The temperature range (20 °C to 40 °C) indicates the extraction treatment temperatures, keeping other extraction conditions constant (pH 4.5, 2 h incubation 200 ppm endoxylanase); e: The time range (2 h to 4 h) indicates the different enzyme extraction times, keeping other extraction conditions constant (pH 4.5, 40 °C, 200 ppm endoxylanase); f: The enzyme concentration range (50 to 400 ppm) indicates the different enzyme concentrations during the extraction of AXs, keeping other extraction conditions constant (pH 4.5, 40 °C for 2 h). Dissimilar superscripts (^{x,y}) highlight significantly different AX extraction yields among the various extraction treatments (P < 0.05).